EAF223: Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)

EAF223: Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)

Es posible que algunos contenidos no estén disponibles en español.

Purpose of this Study

We are doing this study to find out how different imaging techniques can help with the evaluation of glioblastoma.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Have newly diagnosed glioblastoma (IDH wild type)
  • Are planning to receive standard-of-care treatment
  • Will have diagnostic surgery within 7 weeks before joining the study
  • Are not allergic to imaging agents
For more information about this study, please call 919-684-5301.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Looking for Healthy Participants
No

What is Involved?

Description

If you chose to join, you will have at least two study MRI scans.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

Yes

Study Details

Full Title

EAF223: Phase II Glioblastoma Accelerated Biomarkers Learning Environment Trial (GABLE)

Principal Investigator

Annick
Desjardins

Protocol Number

PRO00115772

NCT ID

NCT06319027

Phase

II

Enrollment Status

Pending Open to Enrollment
ClinicalTrials.gov